Brand-name drug
Epogen price, strengths & recalls
Brand of epoetin alfa (generic)
Pharmacies pay $1,618.21 for 10 mL of Epogen 10000 units/mL, 1 mL injection this week, and from $322.67 to $1,618.21 across its 3 priced strengths and forms. It has 1 recall on record, none ongoing. Its official label last changed on July 1, 2026.
Brand- Fair cash price
- $1,871.44
- Strengths
- 3
- Makers
- 1
- Updated
- Nov 11
Epogen price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 2000 units/mL, 1 mL injection Brand | $32.27 | $322.67 / 10 mL | ||
| 4000 units/mL, 1 mL injection Brand | $64.36 | $643.64 / 10 mL | ||
| 10000 units/mL, 1 mL injection Brand | $161.82 | $1,618.21 / 10 mL | ||
| 20000 units/mL injection Brand | Not priced this week | |||
Epogen vs generic epoetin alfa
There is no generic version of Epogen on the market yet.
GenericEpoetin alfa pricesSupply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Epogen
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use EPOGEN safely and effectively. See full prescribing information for EPOGEN. EPOGEN® (epoetin alfa) injection, for intravenous or subcutaneous useInitial U.S. Approval: 1989
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Chronic Kidney Disease:
In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions (5.1)].
No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks [see Dosage and Administration (2.2)].
Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions (5.1)].
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions (5.2)].
To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.4)].
Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage (1.3)].
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage (1.5)].
Discontinue following the completion of a chemotherapy course [see Dosage and Administration (2.4)].
Perisurgery:
Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration (2.5), Warnings and Precautions (5.1)].
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Chronic Kidney Disease:
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1).
No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks (2.2).
Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions (5.1).
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (5.2).
Use the lowest dose to avoid RBC transfusions (2.4).
Use ESAs only for anemia from myelosuppressive chemotherapy (1.3).
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5).
Discontinue following the completion of a chemotherapy course (2.4).
Perisurgery:
Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended (5.1).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- BLA103234 · Amgen
- First approved
- June 1, 1989 (37 years ago)
- Latest approved change
- April 30, 2024
- Approved label
- PDF, May 1, 2024
- Generic makers
- None on the market
Epogen questions
How much does epogen cost without insurance?
Pharmacies pay about $1,618.21 for 10 mL of epogen 10000 units/mL, 1 mL injection ($161.82 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,871.44. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Epogen?
Yes: epoetin alfa. Compare epoetin alfa prices.
Is epogen in shortage?
No shortage is reported for epogen right now. We check the national shortage list every day.
Has epogen been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the epogen label last change?
The official label was last updated on July 1, 2026 (version 137). See what changed.
Talk about epogen
No comments yet. Questions, tips, what worked for you - start the conversation.